Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

This trial is testing the combination of two cancer immunotherapy drugs — pembrolizumab (an immune checkpoint inhibitor) and sunitinib (a targeted therapy) — in patients with advanced thymic carcinoma (a rare cancer of the thymus gland) that has already been treated with chemotherapy. **You may be eligible if...** - You have been diagnosed with advanced thymic carcinoma (the cancer cannot be removed by surgery and/or has spread) - Your cancer has progressed after at least one prior platinum-based chemotherapy regimen - You have measurable tumors on scans - You are in good overall health (ECOG 0–1, meaning you can perform most daily activities) - Your life expectancy is greater than 3 months - You are able to swallow pills - Your blood pressure is controlled (under 140/90) - Heart pumping function (ejection fraction) is adequate **You may NOT be eligible if...** - You have active autoimmune disease requiring treatment - You are currently taking immunosuppressive medications - You have uncontrolled high blood pressure - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, or HIV - You have serious heart, lung, or liver conditions Talk to your doctor to see if this trial is right for you.